(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.33%) $83.57
(-1.16%) $1.619
(-0.03%) $2 346.50
(0.93%) $27.51
(0.31%) $925.00
(0.26%) $0.934
(0.56%) $11.01
(0.08%) $0.800
(0.00%) $92.17
Live Chart Being Loaded With Signals
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally...
Stats | |
---|---|
本日の出来高 | 200.00 |
平均出来高 | 13.00 |
時価総額 | 0.00 |
Last Dividend | $0.411 ( 2022-05-12 ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Vifor Pharma AG 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Vifor Pharma AG 財務諸表
Annual | 2021 |
収益: | $1.82B |
総利益: | $1.15B (63.18 %) |
EPS: | $0.445 |
FY | 2021 |
収益: | $1.82B |
総利益: | $1.15B (63.18 %) |
EPS: | $0.445 |
FY | 2020 |
収益: | $1.71B |
総利益: | $1.00B (58.89 %) |
EPS: | $1.108 |
FY | 2019 |
収益: | $1.88B |
総利益: | $1.12B (59.44 %) |
EPS: | $0.490 |
Financial Reports:
No articles found.
Vifor Pharma AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.371 | 2016-05-02 |
Last Dividend | $0.411 | 2022-05-12 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | $2.44 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.16 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.49 | |
Div. Directional Score | 6.33 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PUBGY | Ex Dividend Knight | 2023-06-30 | Annually | 0 | 0.00% | |
ENLAY | Ex Dividend Knight | 2023-07-24 | Semi-Annually | 0 | 0.00% | |
USNZY | Ex Dividend Junior | 2023-05-01 | Annually | 0 | 0.00% | |
KPLUY | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
CEFC | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
SBSNY | Ex Dividend Junior | 2023-05-02 | Annually | 0 | 0.00% | |
FRRVY | Ex Dividend Junior | 2023-08-04 | Sporadic | 0 | 0.00% | |
ADRNY | Ex Dividend Knight | 2023-08-11 | Annually | 0 | 0.00% | |
YAMHF | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
MNESP | Ex Dividend Knight | 2023-08-15 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.145 | 1.500 | 7.09 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0520 | 1.200 | 8.27 | 9.92 | [0 - 0.3] |
returnOnEquityTTM | 0.0752 | 1.500 | -0.276 | -0.414 | [0.1 - 1] |
payoutRatioTTM | 0.715 | -1.000 | 2.85 | -2.85 | [0 - 1] |
currentRatioTTM | 1.914 | 0.800 | 5.43 | 4.34 | [1 - 3] |
quickRatioTTM | 1.013 | 0.800 | 8.75 | 7.00 | [0.8 - 2.5] |
cashRatioTTM | 1.013 | 1.500 | 5.49 | 8.23 | [0.2 - 2] |
debtRatioTTM | 0.115 | -1.500 | 8.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 22.19 | 1.000 | 2.89 | 2.89 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.622 | 2.00 | 9.46 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.949 | 2.00 | 9.53 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.168 | -1.500 | 9.33 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.632 | 1.000 | 2.80 | 2.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.109 | 1.000 | 9.81 | 9.81 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.898 | 1.000 | 6.12 | 6.12 | [0.2 - 2] |
assetTurnoverTTM | 0.358 | 0.800 | -0.948 | -0.758 | [0.5 - 2] |
Total Score | 10.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 42.95 | 1.000 | 5.76 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0752 | 2.50 | -0.177 | -0.414 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.949 | 2.00 | 9.68 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.622 | 2.00 | 9.46 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.715 | 1.500 | 2.85 | -2.85 | [0 - 1] |
pegRatioTTM | -2.43 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.289 | 1.000 | 5.27 | 0 | [0.1 - 0.5] |
Total Score | 2.49 |
Vifor Pharma AG
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。